secwatch.observer — SEC 8-K summary
======================================

Issuer:     DANAHER CORP /DE/ (DHR)
CIK:        0000313616
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0000313616-26-000002
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Danaher estimates Q4 revenue up mid-single digits YoY; core revenue and FY EPS at high-end of guidance
--------------------------------------------------------------------------------

- Estimated Q4 2025 revenue up mid-single-digit percent YoY; non-GAAP core revenue growth toward high-end of low-single-digit guidance.
- Full-year 2025 adjusted diluted EPS expected toward high-end of $7.70–$7.80 guidance range.
- CEO cites continued strength in Bioprocessing and better-than-expected Life Sciences and Diagnostics revenue in Q4.
- Danaher will report full Q4 and FY2025 earnings on January 28, 2026.
- Presentation at J.P. Morgan Healthcare Conference on January 13; live webcast on Danaher's website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/313616/000031361626000002/0000313616-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/313616/000031361626000002/dhr-20260112.htm
  HTML page:      https://secwatch.observer/filing/0000313616-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer